Ivacaftor: a novel mutation modulating drug.
Article Details
- CitationCopy to clipboard
Kapoor H, Koolwal A, Singh A
Ivacaftor: a novel mutation modulating drug.
J Clin Diagn Res. 2014 Nov;8(11):SE01-5. doi: 10.7860/JCDR/2014/6486.5158. Epub 2014 Nov 20.
- PubMed ID
- 25584290 [ View in PubMed]
- Abstract
Cystic fibrosis (CF) is multisystemic disorder presenting in newborn period to adulthood, predominantly affecting respiratory system. It is caused by mutation in CF transmembrane conductance regulator gene. DeltaF508 is the most common mutation seen worldwide. Supportive management with bronchodilators, anti-inflammatory, mucolytics, antibiotics are the corner stone of therapy. Mutation specific drug, Ivacaftor, was recently approved USFDA in January 2012 for patients carrying G551D mutation. It is approved in patients who are six years and older in 150 mg twice daily dosing schedule with fat containing meals. It improves the lung function and other aspects of disease including weight gain. The side effects like upper respiratory infection, headache, rash, diarrhoea, stomach ache and dizziness are mild and self-limiting. This is excellent example of promise of personalised medicine - targeted drug that treat patients with specific genetic makeup.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Ivacaftor Cytochrome P450 2C9 Protein Humans NoInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareAbrocitinibIvacaftor The serum concentration of Abrocitinib can be increased when it is combined with Ivacaftor. AcenocoumarolIvacaftor The serum concentration of Acenocoumarol can be increased when it is combined with Ivacaftor. AcetohexamideIvacaftor The serum concentration of Acetohexamide can be increased when it is combined with Ivacaftor. Acetylsalicylic acidIvacaftor The serum concentration of Acetylsalicylic acid can be increased when it is combined with Ivacaftor. AlosetronIvacaftor The serum concentration of Alosetron can be increased when it is combined with Ivacaftor.